Dennis J. Carlo

Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotechnology research and development experience. At Hybritech Inc., the first biotechnology company in San Diego, he served as Vice President of Research and Development and Therapeutic Manufacturing. There, he managed a successful program to carry out research and development in the areas of monoclonal antibody and cancer therapy. After Hybritech was acquired by Eli Lilly & Co in 1985, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. At The Immune Response Corporation, he established programs in Autoimmunity, Gene Therapy and HIV and led the product development in successful clinical trials. In 1991, while at Immune Response, Dr. Carlo was awarded “Entrepreneur of the Year” by Ernst & Young LLP. From 2003 to 2006, He served as president of Telos Pharmaceuticals, a private biotechnology company. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.